Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

The findings mean that for those using preexposure prophylaxis with gender-affirming hormone therapy or long-acting hormonal ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) are dedicated to bringing novel treatments to ...

The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes, Bayer ...

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Brekiya® is now available for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Endo's glycerol phenylbutyrate is the first and currently the only FDA-approved generic version of RAVICTI (R) available in the U.S.